Wide Ranks

ALDX

Aldeyra Therapeutics, Inc.

4.94

Top Statistics
Market Cap 294 M Forward PE -11.50 Revenue Growth 0.00 %
Current Ratio 6.80 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -4.80 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 72 M Total Cash Per Share 1.22 Total Debt 15 M
Total Debt To Equity 18.35 Current Ratio 6.80 Book Value Per Share 1.43
All Measures
Short Ratio 879.00 % Message Board Id finmb_47399863 Fax 339 674 6495
Shares Short Prior Month 3 M Return On Equity -0.4305 City Lexington
Uuid 897be644-930d-375e-9e08-51fe235324f6 Previous Close 4.80 First Trade Date Epoch Utc 1 B
Book Value 1.43 Beta 1.43 Total Debt 15 M
Volume 273244 Price To Book 3.46 Fifty Two Week Low 2.69
Total Cash Per Share 1.22 Shares Short Previous Month Date 1 B Target Median Price 10.00
Audit Risk 4 Max Age 86400 Recommendation Mean 1.25
Sand P52 Week Change 0.3133 Target Mean Price 10.00 Net Income To Common -44795640
Short Percent Of Float 0.0786 Implied Shares Outstanding 61 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 711680 Average Volume10days 711680
Total Cash 72 M Next Fiscal Year End 1 B Held Percent Insiders 0.0244
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 4.80 Target Low Price 8.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.27 Open 4.82
Free Cashflow -57674432 State MA Dividend Yield 0.00 %
Return On Assets -0.2345 Time Zone Short Name EST Board Risk 9
Trailing Eps -0.7500 Day Low 4.78 Address1 131 Hartwell Avenue
Shares Outstanding 59 M Compensation Risk 6 Price Hint 4
Target High Price 12.00 Website https://www.aldeyra.com 52 Week Change 0.7834
Average Volume 498051 Forward Eps -0.6100 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 424.10 % Is_sp_500 False
Regular Market Day High 4.95 Profit Margins 0.00 % Debt To Equity 18.35
Fifty Two Week High 6.55 Day High 4.95 Shares Short 3 M
Regular Market Open 4.82 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0653 Operating Cashflow -30671462
Currency USD Time Zone Full Name America/New_York Market Cap 294 M
Is_nasdaq_100 False Zip 02421 Quote Type EQUITY
Industry Biotechnology Long Name Aldeyra Therapeutics, Inc. Overall Risk 7
Regular Market Day Low 4.78 Held Percent Institutions 0.7779 Current Price 4.94
Address2 Suite 320 Enterprise To Ebitda -4.80 Financial Currency USD
Current Ratio 6.80 Industry Disp Biotechnology Number Of Analyst Opinions 8
Country United States Float Shares 43 M Two Hundred Day Average 4.37
Governance Epoch Date 1 B Enterprise Value 237 M Forward PE -11.50
Regular Market Volume 273244 Ebitda -49385308 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases.

Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases.

The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.

In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy.

The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.